GLPwatch
A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
NCT03724981 · Completed
Last updated 2026-05-28This study is testing which injection pen—dulaglutide or semaglutide—people with type 2 diabetes prefer using.
Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) study
Participants 312 people
Who can join Ages 18+ · all sexes
Timeline Started 2018-10 · est. completion 2019-04
Where 14 sites · United States
What this study is testing ClinicalTrials.gov NCT03724981 ↗
Description as written by the study sponsor.
In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered.
Treatments tested
- Dulaglutide Pen Drug
Injected on a practice pad.
- Semaglutide Pen Drug
Injected on a practice pad.
| Main thing measured | Participant Preference Between 2 Injection Devices Based on Global Preference Item |
|---|---|
| Sponsor | Eli Lilly and Company |
| Conditions studied | Diabetes Mellitus, Type 2 |
| GLP-1 drugs | semaglutide, dulaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03724981 ↗